Pursuing both targeted therapeutics and partnered programs.

Product Pipeline

TaRGeT Zip-Codes ™ can be used to deliver a variety of therapeutic payload classes.

Library Zip Code Development Program

Kodikaz is developing a library of cell-specific TaRGeT Zip-Codes ™. Active programs are being explored in the following oncology areas:

-Lung

-Eye

-Colon

-Lymphoma

Contact us for partnering information or if you would like to explore specific cells development.

Disease Statistics

Kodikaz is committed to transforming the lives of patients by developing and delivering potentially curative treatments for various cancers, initially targeting Multiple Myeloma and Pancreatic cancer.

About Pancreatic cancer

  • This year, an estimated 56,770 adults (29,940 men and 26,830 women) in the United States will be diagnosed with pancreatic cancer. The disease causes approximately 3% of all cancers. Incidence rates are 25% higher in black people than in white people.
  • It is estimated that 45,750 deaths (23,800 men and 21,950 women) from this disease will occur this year. Pancreatic cancer is the ninth most common cancer in women and the tenth most common cancer in men. It is the fourth leading cause of cancer death in men and women. It accounts for 7% of all cancer deaths. As explained in the Introduction, most pancreatic cancers (93%) are exocrine adenocarcinoma.
  • The 5-year survival rate tells you what percent of people live at least 5 years after the cancer is found. Percent means how many out of 100. The 5-year survival rate for people with pancreatic cancer is 9%. Survival rates are based on many factors, including the specific stage of disease when it is diagnosed.
  • Pancreatic cancer is often difficult to diagnose. This is because there are no specific, cost-effective screening tests that can easily and reliably find early-stage pancreatic cancer in people who have no symptoms. This means it is often not found until later stages when the cancer can no longer be removed with surgery and has spread from the pancreas to other parts of the body.
  • If the cancer is detected at an early stage when surgical removal of the tumor is possible, the 5-year survival rate is 34%. About 10% of people are diagnosed at this stage. If the cancer has spread to surrounding tissues or organs, the 5-year survival rate is 12%. For the 52% of people who are diagnosed after the cancer has spread to a distant part of the body, the 5-year survival rate is 3%.

(Source: https://www.cancer.net/cancer-types/pancreatic-cancer/statistics)

About Multiple Myeloma

  • Multiple myeloma is not a common cancer but is the second most common blood cancer after non-Hodgkin lymphoma in the United States. The lifetime risk for multiple myeloma is about 1 in 132. This year, an estimated 32,110 adults (18,130 men and 13,980 women) in the United States will be diagnosed with multiple myeloma.
  • It is estimated that 12,960 deaths (6,990 men and 5,970 women) from this disease will occur this year.
  • The 5-year survival rate tells you what percent of people live at least 5 years after the cancer is found. Percent means how many out of 100. The 5-year survival rate for people with multiple myeloma is over 50%. For the 5% of people who are diagnosed at an early stage, the 5-year survival rate is 72%. If the cancer has spread to a distant part of the body, the 5-year survival rate is almost 50%.
  • Survival rates have steadily increased over the last decade, so the 5-year survival rate may underestimate the impact of recent progress made in the treatment of this disease. Moreover, several factors affect an individual’s survival, such as the person’s age and overall health. For instance, it is known that survival rates are higher in younger people than in older people.

(Source: https://www.cancer.net/cancer-types/multiple-myeloma/statistics)